CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.59B, above the global median of $1.15B
- PositionOperating margin is 459241.4%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.59BUSDvs all stocks (USD)
Revenue (TTM)
65.50MUSDvs all stocks (USD)
Beta
1.62xvs all stocks
52-Week Change
70.83%vs all stocks
Market Capitalization
1.59BUSDvs all stocks (USD)
Enterprise Value
1.21BUSDvs all stocks (USD)
Forward P/E
-4.06xvs Biotechnology peers
Price to Sales (TTM)
24.28xvs Biotechnology peers
Price to Book (MRQ)
1.87xvs Biotechnology peers
Enterprise to Revenue
18.47xvs Biotechnology peers
Enterprise to EBITDA
-2.68xvs Biotechnology peers
Return on Assets (TTM)
-24.79%vs Biotechnology peers
Return on Equity (TTM)
-47.69%vs Biotechnology peers
Revenue (TTM)
65.50MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4650USDUpdated Jul 19, 2026Quarterly Revenue Growth
-100.06%vs Biotechnology peers
Gross Profit (TTM)
-371.20MUSDvs all stocks (USD)
EBITDA (TTM)
-451.05MUSDvs all stocks (USD)
Net Income (TTM)
-442.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-102.29%vs Biotechnology peers
Operating Cash Flow (TTM)
-446.05MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-214.93MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
66.52MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
26.00KUSDFY2025 · Dec 31, 2025Gross Profit
66.49MUSDFY2025 · Dec 31, 2025Operating Income
-479.51MUSDvs all stocks (USD)
Pre-tax Income
-437.77MUSDFY2025 · Dec 31, 2025Income Tax Expense
217.00KUSDFY2025 · Dec 31, 2025Net Income
-437.99MUSDFY2025 · Dec 31, 2025EBIT
-479.51MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-469.74MUSDFY2025 · Dec 31, 2025Research & Development
455.97MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
92.07MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.04MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
40.24MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.16USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.16USDFY2025 · Dec 31, 2025Basic Shares Outstanding
138.52MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
138.52MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-437.99MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-392.09MUSDFY2025 · Dec 31, 2025Free Cash Flow
-396.67MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
241.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-437.99MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.68MUSDFY2025 · Dec 31, 2025Stock-based Compensation
49.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
156.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.01MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.58MUSDFY2025 · Dec 31, 2025Purchase of Investments
-886.33MUSDFY2025 · Dec 31, 2025Sale of Investments
1.20BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
310.37MUSDFY2025 · Dec 31, 2025Other Financing Charges
-361.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-361.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
161.23MSharesUpdated Jul 19, 2026Float Shares
128.76MSharesUpdated Jul 19, 2026Shares Short
19.19MSharesUpdated Jul 19, 2026Short Ratio
8.17daysvs all stocks
Short % of Shares Outstanding
11.52%vs all stocks
% Held by Insiders
6.59%vs all stocks
% Held by Institutions
80.77%vs all stocks
Total Cash (MRQ)
476.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.82USDUpdated Jul 19, 2026Total Debt (MRQ)
95.58MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1176xvs Biotechnology peers
Current Ratio (MRQ)
7.11xvs Biotechnology peers
Book Value per Share (MRQ)
5.04USDUpdated Jul 19, 2026Total Assets
1.00BUSDvs all stocks (USD)
Total Current Assets
514.08MUSDFY2025 · Dec 31, 2025Total Liabilities
237.55MUSDFY2025 · Dec 31, 2025Total Non-current Assets
488.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
144.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
92.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
232.19MUSDFY2025 · Dec 31, 2025Other Short-term Investments
234.83MUSDFY2025 · Dec 31, 2025Accounts Payable
9.80MUSDFY2025 · Dec 31, 2025Short-term Debt
8.80MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
89.05MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
55.68MUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.20BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
765.28MUSDvs all stocks (USD)
52-Week Low
4.16USDUpdated Jul 19, 202652-Week High
11.66USDUpdated Jul 19, 202652-Week Change
70.83%vs all stocks
Beta
1.62xvs all stocks
50-Day MA
9.35USDUpdated Jul 19, 2026200-Day MA
7.90USDUpdated Jul 19, 2026Avg 10-Day Volume
1.61MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.10MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.14USDUpdated Jul 19, 2026Other Income / Expense
1.50MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 459241.4%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 4,592.414Industry median: -0.24Industry P95: 0.38Peers compared: 197
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 24.28Revenue Growth YoY: -1.00
Financial Health
Altman Z-Score 1.34: grey zoneSignificant
Altman Z-Score: 1.34
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.59B, above the global median of $1.15BNotable
Market cap (USD): 1,590,388,114Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Intellia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Yantai Dongcheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Harbin Gloria Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hebei Sinopack Electronic Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Samsung Electronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity